- £43.40m
- £46.58m
- $29.49m
- 48
- 21
- 75
- 43
Annual balance sheet for Tissue Regenix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3.16 | 13.1 | 7.71 | 5.95 | 4.65 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.1 | 3.7 | 3.6 | 4.64 | 3.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 13.4 | 27.5 | 22.1 | 22 | 19.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.13 | 7.81 | 9.1 | 8.94 | 9.02 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Total Assets | 40.4 | 50.2 | 46.2 | 46 | 43.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.13 | 4.46 | 4.36 | 6.64 | 4.74 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Liabilities | 7.01 | 11.3 | 11.9 | 14.8 | 13.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 33.4 | 38.9 | 34.3 | 31.3 | 30.1 |
| Total Liabilities & Shareholders' Equity | 40.4 | 50.2 | 46.2 | 46 | 43.2 |
| Total Common Shares Outstanding |